Alamar NULISA at AAIC 2026
Analysis based on 16 articles · First reported Jul 07, 2026 · Last updated Jul 10, 2026
The strong presence at AAIC may boost Alamar's visibility and credibility in the Alzheimer's biomarker space, potentially driving adoption and revenue. However, the event is a scientific conference, not a product launch, so immediate market impact is limited.
Alamar Biosciences announced that its NULISA platform will be featured in over 140 poster and session presentations at the Alzheimer s Association (AAIC) in United Kingdom — London, July 12-15, 2026. The company will host a workshop showcasing new data on eMTBR-Tau and BD-pTau217 assays for Alzheimer's detection and staging. The volume of presentations quadrupled from the previous AAIC, indicating growing adoption of NULISA technology in Alzheimer's research.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard